( MENAFN - JCN NewsWire) FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the treatment of Early Alzheimer's disease LEQEMBI is the only ...
Cerebral proliferative angiopathy (CPA) is a rare vascular disorder that affects normal blood circulation in the brain. Although the structural changes in CPA can be characterized using standard ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback